Premium
CBP/p300 and muscle differentiation: no HAT, no muscle
Author(s) -
Polesskaya A.,
Naguibneva I.,
Fritsch L.,
Duquet A.,
AitSiAli S.,
Robin P.,
Vervisch A.,
Pritchard L.L.,
Cole P.,
HarelBellan A.
Publication year - 2001
Publication title -
the embo journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.484
H-Index - 392
eISSN - 1460-2075
pISSN - 0261-4189
DOI - 10.1093/emboj/20.23.6816
Subject(s) - humanities , biology , art
Terminal differentiation of muscle cells follows a precisely orchestrated program of transcriptional regulatory events at the promoters of both muscle‐specific and ubiquitous genes. Two distinct families of transcriptional co‐activators, GCN5/PCAF and CREB‐binding protein (CBP)/p300, are crucial to this process. While both possess histone acetyl‐transferase (HAT) activity, previous studies have failed to identify a requirement for CBP/p300 HAT function in myogenic differentiation. We have addressed this issue directly using a chemical inhibitor of CBP/p300 in addition to a negative transdominant mutant. Our results clearly demonstrate that CBP/p300 HAT activity is critical for myogenic terminal differentiation. Furthermore, this requirement is restricted to a subset of events in the differentiation program: cell fusion and specific gene expression. These data help to define the requirements for enzymatic function of distinct coactivators at different stages of the muscle cell differentiation program.